FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2126557788> ?p ?o ?g. }

• W2126557788 endingPage "8" @default.
• W2126557788 startingPage "1" @default.
• W2126557788 abstract "Journal of NeurochemistryVolume 49, Issue 1 p. 1-8 Biochemical Events in the Development of Parkinsonism Induced by 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Thomas P. Singer, Corresponding Author Thomas P. Singer Departments of Biochemistry and Biophysics, Division of Toxicology, and Departments of Pharmacy and Pharmacology, University of California, San Francisco; and Veterans Administration Medical Center, San Francisco, California, U.S.A.Address correspondence and reprint requests to Dr. T. P. Singer at Departments of Biochemistry and Biophysics, Molecular Biology Division (Dept. 151-S), Veterans Administration Medical Center, 4150 Clement Street, San Francisco, CA 94109, U.S.A.Search for more papers by this authorNeal Castagnoli Jr., Neal Castagnoli Jr. Departments of Biochemistry and Biophysics, Division of Toxicology, and Departments of Pharmacy and Pharmacology, University of California, San Francisco; and Veterans Administration Medical Center, San Francisco, California, U.S.A.Search for more papers by this authorRona R. Ramsay, Rona R. Ramsay Departments of Biochemistry and Biophysics, Division of Toxicology, and Departments of Pharmacy and Pharmacology, University of California, San Francisco; and Veterans Administration Medical Center, San Francisco, California, U.S.A.Search for more papers by this authorAnthony J. Trevor, Anthony J. Trevor Departments of Biochemistry and Biophysics, Division of Toxicology, and Departments of Pharmacy and Pharmacology, University of California, San Francisco; and Veterans Administration Medical Center, San Francisco, California, U.S.A.Search for more papers by this author Thomas P. Singer, Corresponding Author Thomas P. Singer Departments of Biochemistry and Biophysics, Division of Toxicology, and Departments of Pharmacy and Pharmacology, University of California, San Francisco; and Veterans Administration Medical Center, San Francisco, California, U.S.A.Address correspondence and reprint requests to Dr. T. P. Singer at Departments of Biochemistry and Biophysics, Molecular Biology Division (Dept. 151-S), Veterans Administration Medical Center, 4150 Clement Street, San Francisco, CA 94109, U.S.A.Search for more papers by this authorNeal Castagnoli Jr., Neal Castagnoli Jr. Departments of Biochemistry and Biophysics, Division of Toxicology, and Departments of Pharmacy and Pharmacology, University of California, San Francisco; and Veterans Administration Medical Center, San Francisco, California, U.S.A.Search for more papers by this authorRona R. Ramsay, Rona R. Ramsay Departments of Biochemistry and Biophysics, Division of Toxicology, and Departments of Pharmacy and Pharmacology, University of California, San Francisco; and Veterans Administration Medical Center, San Francisco, California, U.S.A.Search for more papers by this authorAnthony J. Trevor, Anthony J. Trevor Departments of Biochemistry and Biophysics, Division of Toxicology, and Departments of Pharmacy and Pharmacology, University of California, San Francisco; and Veterans Administration Medical Center, San Francisco, California, U.S.A.Search for more papers by this author First published: July 1987 https://doi.org/10.1111/j.1471-4159.1987.tb03384.xCitations: 205Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References Baker J. K., Borne R. R., Davis M. M., and Waters I. W. (1984) Metabolism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse liver preparations. Biochem. Biophys. Res. Commun. 125, 484–490. Beinert H., Palmer G., Cremona T., and Singer T. P. (1965) Kinetic studies on reduced diphosphopyridine nucleotide dehydrogenase by electron paramagnetic resonance spectroscopy. J. Biol. Chem. 240, 475–480. Bradbury A. J., Costall B., Domeney A. M., Jenner P., Kelly M. E., Marsden C. D., and Naylor R. J. (1986) 1-Methyl-4-phenylpyridine is neurotoxic to the nigrostriatal dopamine pathway. Nature 319, 56–57. Cashman J. R. and Zeigler D. M. (1986) Contribution of N-oxygenation to the metabolism of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) by various liver preparations. Mol. Pharmacol. 29, 163–167. Chiba K., Trevor A., and Castagnoli N. Jr (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120, 574–578. Chiba K., Trevor A. J., and Castagnoli N. Jr (1985) Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes. Biochem. Biophys. Res. Commun. 128, 1228–1232. D'Amato R. J., Lipman Z. P., and Snyder S. H. (1986) Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. Science 231, 987–989. Di Monte D., Sandy M. S., Ekstrom G., and Smith M. T. (1986a) Comparative studies on the mechanisms of paraquat and 1-methyl-4-phenylpyridine toxicity. Biochem. Biophys. Res. Commun. 137, 303–309. Di Monte D., Jewell S. A., Ekstrom G., Sandy M. S., and Smith M. T. (1986b) 1-Methyl-4-phenyl-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) cause rapid ATP depletion in isolated hepatocytes. Biochem. Biophys. Res. Commun. 137, 310–315. Fritz R. R., Abell C. W., Patel N. T., Gessner W., and Brossi A. (1985) Metabolism of the neurotoxin MPTP by human liver monoamine oxidase B. FEBS Lett. 186, 224–227. Heikkila R. E., Manzino L., Cabbat F. S., and Duvoisin R. C. (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311, 467–469. Heikkila R. E., Nicklas W. J., and Duvoisin R. C. (1985) Dopaminergic toxicity after stereotaxic administration of the 1-methyl-4-pyridiniumion (MPP+) to rats. Neurosci. Lett. 59, 135–140. Morgan D. J., Singer T. P., and Casida J. E. (1968) Binding sites of rotenone, piericidin A., and Amytal in the respiratory chain. J. Biol. Chem. 243, 834–843. Irwin I. and Langston J. W. (1985) Selective accumulation of MPP+ in the substantia nigra: a key to neurotoxicity Life Sci. 36, 207–212. Javitch J. A., D'Amato R. J., Strittmatter S. M., and Snyder S. H. (1985) Parkinsonism-inducing neurotoxin, N-methyM-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. USA 82, 2173–2177. Johannessen J. N., Chiueh C. C., Burns R. S., and Markey S. P. (1985a) Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects. Life Sci. 36, 219–224. Johannessen J. N., Adams J. D., Schuller H. M., Bacon J. B., and Markey S. P. (1985b) 1-Methyl-4-phenylpyridine (MPP+) induces oxidative stress in the rodent. Life Sci. 38, 743–749. Kowal A. T., Morningstar J. E., Johnson M. K., Ramsay R. R., and Singer T. P. (1986) Spectroscopic characterization of the number and type of iron-sulfur clusters in NADH-ubiquinone oxidoreductase. J. Biol. Chem. 261, 9239–9245. Langston J. W., Ballard P., Tetrud J. W., and Irwin I. (1983) Chronic parkinsonism in humans due to a product of meperi-dine-analog synthesis. Science 219, 979–980. Langston J. W., Irwin I., Langston E. B., and Forno L. S. (1984) Pargyline prevents MPTP-induced parkinsonism in primates. Science 225, 1480–1482. Markey J. P., Johannessen J. N., Chiueh C. C., Burns R. S., and Herkenham M. A. (1984) Intra-neuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 311, 464–467. Melamed E., Rosenthal J., Cohen O., Globus M., and Uzzan A. (1985) Dopamine but not epinephrine or serotonin uptake inhibitors protect mice against neurotoxicity of MPTP. Eur. J. Pharmacol. 116, 179–181. Mytilineou C., and Cohen G. (1984) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine destroys dopamine neurons in explants of rat embryo mesencephalon. Science 225, 529–531. Nicklas W. J., Vyas I., and Heikkila R. E. (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci. 36, 2503–2508. Peterson L. A., Caldera P. S., Trevor A., Chiba K., and Castagnoli N. Jr (1985) Studies on the 1-methyl-4-phenyl-2,3-dihydro-pyridinium species 2,3-MPDP+, the monoamine oxidase catalyzed oxidation product of the nigrostriatal toxin MPTP. J. Med. Chem. 28, 1432–1436. Poirier J. and Barbeau A. (1985) A catalyst function for MPTP in superoxide formation. Biochem. Biophys. Res. Commun. 131, 1284–1289. Poirier J., Donaldson J., and Barbeau A. (1985) The specific vulnerability of the substantia nigra to MPTP is related to the presence of transition metals. Biochem. Biophys. Res. Commun. 128, 25–33. Ramsay R. R., and Singer T. P. (1986) Energy-dependent uptake of Af-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J. Biol. Chem. 261, 7585–7587. Ramsay R. R., Salach J. L., and Singer T. P. (1986a) Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) and its relation to the inhibition of mitochondrial NADH-linked substrates by MPP+. Biochem. Biophys. Res. Commun. 134, 743–748. Ramsay R. R., Salach J. L., Dadgar J., and Singer T. P. (1986b) Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism. Biochem. Biophys. Res. Commun. 135, 269–275. Ramsay R. R., Dadgar J., Trevor A. J., and Singer T. P. (1986c) Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP. Life Sci. 39, 581–588. Ramsay R. R., Salach J. L., McKeown K., Johnson M. K., Kowal A. T., Johnson A. E., Booth R., and Singer T. P. (1987) Action of pyridine derivatives on mitochondrial respiration and NADH dehydrogenase and their carrier-mediated uptake into mitochondria. Biochem. Biophys. Res. Commun. (in press). Salach J. I., Singer T. P., Castagnoli N. Jr, and Trevor A. (1984) Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP. Biochem. Biophys. Res. Commun. 125, 831–835. Sayre L. M., Arora P. K., Feke S. C., and Urbach F. L. (1986) Mechanism of induction of Parkinson's disease by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Chemical and electrochemical characterization of a geminal-dimethyl-blocked analogue of a postulated toxic metabolite. J. Am. Chem. Soc. 108, 2464–2466. Schmidt C. J., Bruckwick E., and Lovenberg W. (1985) Lack of evidence supporting a role for dopamine in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Eur. J. Pharmacol. 113, 149–150. Singer T. P., Salach J. I., and Crabtree D. (1985) Reversible inhibition and mechanism-based irreversible inactivation of monoamine oxidases by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Biochem. Biophys. Res. Commun. 127, 341–346. Singer T. P., Salach J. I., Castagnoli N. Jr, and Trevor A. J. (1986) Interactions of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine with monoamine oxidases. Biochem. J. 235, 785–789. SnyderS. H. and D'Amato R. J. (1985) Predicting Parkinson's disease. Nature 317, 198–199. Sundstrom E. and Jonnson G. (1985) Pharmacological interference with the neurotoxic actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholaminergic neurons in the mouse. Eur. J. Pharmacol. 110, 293–299. Trevor A. J., Castagnoli N. Jr, and Singer T. P. (1987) Pharmacology and toxicology of MPTP: a neurotoxic by-product of illicit designer drug chemistry, in Cocaine, Marijuana, Designer Drugs: Chemistry, Pharmacology and Behavior ( K. Redda, C. A. Walker, G. Barnett, and L. D. Fannin), in press. CRC Press, Boca Raton , Florida . Weissman J., Trevor A. J., Chiba K., Peterson L. A., Caldera P., and Castagnoli N. Jr (1985) Metabolism of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by liver homogenate fractions. J. Med. Chem. 28, 997–1001. Westlund K. N., Denney R. M., Kochenperger L. M., Rose R. M., and Abell C. W. (1985) Distinct monoamine oxidase A and B populations in primate brain. Science 230, 181–183. Wu E. Y., Chiba K., Trevor A. J., and Castagnoli N. Jr (1986) Interactions of the 1-methyl-4-phenyl-2,3-dihydropyridinium species with synthetic dopamine-melanin. Life Sci. 39, 1695–1700. Citing Literature Volume49, Issue1July 1987Pages 1-8 ReferencesRelatedInformation" @default.
• W2126557788 created "2016-06-24" @default.
• W2126557788 creator A5014093069 @default.
• W2126557788 creator A5043739803 @default.
• W2126557788 creator A5045316297 @default.
• W2126557788 creator A5075420510 @default.
• W2126557788 date "1987-07-01" @default.
• W2126557788 modified "2023-09-27" @default.
• W2126557788 title "Biochemical Events in the Development of Parkinsonism Induced by 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine" @default.
• W2126557788 cites W134549244 @default.
• W2126557788 cites W1499646772 @default.
• W2126557788 cites W1507356284 @default.
• W2126557788 cites W1602098835 @default.
• W2126557788 cites W1969800514 @default.
• W2126557788 cites W1971062646 @default.
• W2126557788 cites W1983818310 @default.
• W2126557788 cites W1992333288 @default.
• W2126557788 cites W1996774271 @default.
• W2126557788 cites W2000956059 @default.
• W2126557788 cites W2003020347 @default.
• W2126557788 cites W2005102504 @default.
• W2126557788 cites W2012456723 @default.
• W2126557788 cites W2014260365 @default.
• W2126557788 cites W2014444130 @default.
• W2126557788 cites W2018388019 @default.
• W2126557788 cites W2023909084 @default.
• W2126557788 cites W2026259715 @default.
• W2126557788 cites W2026383921 @default.
• W2126557788 cites W2026484607 @default.
• W2126557788 cites W2027432236 @default.
• W2126557788 cites W2029528673 @default.
• W2126557788 cites W2029793678 @default.
• W2126557788 cites W2030296763 @default.
• W2126557788 cites W2033064740 @default.
• W2126557788 cites W2034919334 @default.
• W2126557788 cites W2038557175 @default.
• W2126557788 cites W2041734419 @default.
• W2126557788 cites W2043839194 @default.
• W2126557788 cites W2047648704 @default.
• W2126557788 cites W2062003647 @default.
• W2126557788 cites W2066623127 @default.
• W2126557788 cites W2070849668 @default.
• W2126557788 cites W2071953515 @default.
• W2126557788 cites W2077260129 @default.
• W2126557788 cites W2078259114 @default.
• W2126557788 cites W2084638599 @default.
• W2126557788 cites W2086208850 @default.
• W2126557788 cites W2086518349 @default.
• W2126557788 cites W68628203 @default.
• W2126557788 doi "https://doi.org/10.1111/j.1471-4159.1987.tb03384.x" @default.
• W2126557788 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3495634" @default.
• W2126557788 hasPublicationYear "1987" @default.
• W2126557788 type Work @default.
• W2126557788 sameAs 2126557788 @default.
• W2126557788 citedByCount "237" @default.
• W2126557788 countsByYear W21265577882012 @default.
• W2126557788 countsByYear W21265577882013 @default.
• W2126557788 countsByYear W21265577882014 @default.
• W2126557788 countsByYear W21265577882015 @default.
• W2126557788 countsByYear W21265577882016 @default.
• W2126557788 countsByYear W21265577882017 @default.
• W2126557788 countsByYear W21265577882019 @default.
• W2126557788 countsByYear W21265577882020 @default.
• W2126557788 countsByYear W21265577882021 @default.
• W2126557788 countsByYear W21265577882022 @default.
• W2126557788 countsByYear W21265577882023 @default.
• W2126557788 crossrefType "journal-article" @default.
• W2126557788 hasAuthorship W2126557788A5014093069 @default.
• W2126557788 hasAuthorship W2126557788A5043739803 @default.
• W2126557788 hasAuthorship W2126557788A5045316297 @default.
• W2126557788 hasAuthorship W2126557788A5075420510 @default.
• W2126557788 hasConcept C126322002 @default.
• W2126557788 hasConcept C15744967 @default.
• W2126557788 hasConcept C169760540 @default.
• W2126557788 hasConcept C185592680 @default.
• W2126557788 hasConcept C2776525014 @default.
• W2126557788 hasConcept C2779134260 @default.
• W2126557788 hasConcept C71924100 @default.
• W2126557788 hasConceptScore W2126557788C126322002 @default.
• W2126557788 hasConceptScore W2126557788C15744967 @default.
• W2126557788 hasConceptScore W2126557788C169760540 @default.
• W2126557788 hasConceptScore W2126557788C185592680 @default.
• W2126557788 hasConceptScore W2126557788C2776525014 @default.
• W2126557788 hasConceptScore W2126557788C2779134260 @default.
• W2126557788 hasConceptScore W2126557788C71924100 @default.
• W2126557788 hasIssue "1" @default.
• W2126557788 hasLocation W21265577881 @default.
• W2126557788 hasLocation W21265577882 @default.
• W2126557788 hasOpenAccess W2126557788 @default.
• W2126557788 hasPrimaryLocation W21265577881 @default.
• W2126557788 hasRelatedWork W1589858513 @default.
• W2126557788 hasRelatedWork W2025783008 @default.
• W2126557788 hasRelatedWork W2103464098 @default.
• W2126557788 hasRelatedWork W2317757025 @default.
• W2126557788 hasRelatedWork W2468827978 @default.
• W2126557788 hasRelatedWork W2589190912 @default.
• W2126557788 hasRelatedWork W2748952813 @default.
• W2126557788 hasRelatedWork W2899084033 @default.

• next